These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 31726389)
1. A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein. Li H; Liu J; Xiao X; Sun S; Zhang H; Zhang Y; Zhou W; Zhang B; Roy M; Liu H; Ye M; Wang Z; Liu-Smith F; Liu J Mol Ther Nucleic Acids; 2019 Dec; 18():727-738. PubMed ID: 31726389 [TBL] [Abstract][Full Text] [Related]
2. Cell surface CD63 increased by up-regulated polylactosamine modification sensitizes human melanoma cells to the BRAF inhibitor PLX4032. Kudo K; Yoneda A; Sakiyama D; Kojima K; Miyaji T; Yamazaki M; Yaita S; Hyodo T; Satow R; Fukami K FASEB J; 2019 Mar; 33(3):3851-3869. PubMed ID: 30508500 [TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
4. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467 [TBL] [Abstract][Full Text] [Related]
5. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Ravnan MC; Matalka MS Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884 [TBL] [Abstract][Full Text] [Related]
6. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells. Zhao K; Lu Y; Chen Y; Cheng J; Zhang W Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467 [TBL] [Abstract][Full Text] [Related]
11. Rescue of cell cycle progression in BRAF Toress-Collado AX; Nazarian R; Jazirehi AR Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920 [TBL] [Abstract][Full Text] [Related]
12. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539 [TBL] [Abstract][Full Text] [Related]
13. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149 [TBL] [Abstract][Full Text] [Related]
14. Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463 [No Abstract] [Full Text] [Related]
15. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model. Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821 [TBL] [Abstract][Full Text] [Related]
16. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF Torres-Collado AX; Knott J; Jazirehi AR Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29795041 [TBL] [Abstract][Full Text] [Related]
17. Targeting CDC7 sensitizes resistance melanoma cells to BRAF Gad SA; Ali HEA; Gaballa R; Abdelsalam RM; Zerfaoui M; Ali HI; Salama SH; Kenawy SA; Kandil E; Abd Elmageed ZY Sci Rep; 2019 Oct; 9(1):14197. PubMed ID: 31578454 [TBL] [Abstract][Full Text] [Related]
18. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma. Pedini F; De Luca G; Felicetti F; Puglisi R; Boe A; Arasi MB; Fratini F; Mattia G; Spada M; Caporali S; Biffoni M; Giuliani A; Carè A; Felli N Mol Oncol; 2019 Sep; 13(9):1836-1854. PubMed ID: 31115969 [TBL] [Abstract][Full Text] [Related]
19. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Martin S; Dudek-Perić AM; Maes H; Garg AD; Gabrysiak M; Demirsoy S; Swinnen JV; Agostinis P Biochem Pharmacol; 2015 Feb; 93(3):290-304. PubMed ID: 25529535 [TBL] [Abstract][Full Text] [Related]
20. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Kim A; Cohen MS Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]